Thermo Fisher Scientific reported Q3 2024 revenue of $10.60 billion, flat compared to Q3 2023. GAAP EPS was $4.25, down from $4.42 last year, while adjusted EPS reached $5.28. The company saw sequential improvement in growth across all metrics.Thermo Fisher launched several innovative products, including the Thermo Scientific Iliad scanning transmission electron microscope and new life sciences research tools. The company expanded its pharma services capabilities and clinical research network. Management highlighted strong commercial performance and continued execution of their growth strategy.Based on Q3 results, Thermo Fisher raised its full-year 2024 adjusted EPS guidance to $21.35-$22.07, while maintaining revenue guidance of $42.4-$43.3 billion. The company's free cash flow for Q3 was $1.92 billion, demonstrating continued financial strength and ability to invest in future growth.

Thermo Fisher Scientific reported Q3 2024 revenue of $10.60 billion, flat compared to Q3 2023. GAAP EPS was $4.25, down from $4.42 last year, while adjusted EPS reached $5.28. The company saw sequential improvement in growth across all metrics.Thermo Fisher launched several innovative products, including the Thermo Scientific Iliad scanning transmission electron microscope and new life sciences research tools. The company expanded its pharma services capabilities and clinical research network. Management highlighted strong commercial performance and continued execution of their growth strategy.Based on Q3 results, Thermo Fisher raised its full-year 2024 adjusted EPS guidance to $21.35-$22.07, while maintaining revenue guidance of $42.4-$43.3 billion. The company's free cash flow for Q3 was $1.92 billion, demonstrating continued financial strength and ability to invest in future growth.